Tachycardia Market Research Report – Forecast to 2027

Tachycardia Market Information: By type (Atrial Fibrillation, Atrial Flutter), by Treatment (Vagal Maneuvers, Medications), by Diagnosis (Imaging Tests, Electrocardiogram), and End-User (Hospitals & Clinics, Specialty Centers) Forecast Till 2027

ID: MRFR/MED/4427-HCR | February 2021 | Region: Global | 100 Pages         

Table Of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Tachycardia Market, By Type

6.1 Introduction

6.2 Atrial Fibrillation

6.2.1 Market Estimates & Forecast, 2020–2027

6.3 Atrial Flutter

6.3.1 Market Estimates & Forecast, 2020–2027

6.4 Supraventricular Tachycardia

6.4.1 Market Estimates & Forecast, 2020–2027

6.5 Ventricular Tachycardia

6.5.1 Market Estimates & Forecast, 2020–2027

6.6 Ventricular Fibrillation

6.6.1 Market Estimates & Forecast, 2020–2027

6.7 Tachy-Brady Syndrome

6.7.1 Market Estimates & Forecast, 2020–2027

7. Global Tachycardia Market, By Treatment

7.1 Introduction

7.2 Vagal Maneuvers

7.2.1 Market Estimates & Forecast, 2020–2027

7.3 Medications

7.3.1 Market Estimates & Forecast, 2020–2027

7.4 Cardioversion

7.4.1 Market Estimates & Forecast, 2020–2027

8. Global Tachycardia Market, By Diagnosis

8.1 Introduction

8.2 Imaging Tests

8.2.1 Echocardiogram

8.2.2 MRI

8.2.3 CT Scan

8.2.4 Coronary Angiogram

8.2.5 Chest X-Ray

8.2.6 Market Estimates & Forecast, 2020–2027

8.3 Electrocardiogram (ECG)

8.3.1 Market Estimates & Forecast, 2020–2027

8.4 Stress Test

8.4.1 Market Estimates & Forecast, 2020–2027

9. Global Tachycardia Market, By End-User

9.1 Introduction

9.2 Hospitals & Clinics

9.2.1 Market Estimates & Forecast, 2020–2027

9.3 Specialty Centers

9.3.1 Market Estimates & Forecast, 2020–2027

9.4 Ambulatory Surgical Centers

9.4.1 Market Estimates & Forecast, 2020–2027

10 Global Tachycardia Market, By Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 U.K.

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest Of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic Of Korea

10.4.6 Rest Of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest Of The Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Abbott Laboratories

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Terumo Corporation

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Cardinal Health, Inc.

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Cardiva Medical, Inc.

12.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

12.5 Medtronic PLC

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial Overview

12.5.4 Key Developments

12.6 Morris Innovative, Inc.

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Essential Medical, Inc.

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs Of The Market

13.2 Key Companies To Watch

13.3 Prediction Of The Pharmaceutical Industry

14 Appendix

LIST OF TABLES

Table 1 Tachycardia Industry Synopsis, 2020–2027

Table 2 Global Tachycardia Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Tachycardia Market, By Region, 2020–2027, (USD Million)

Table 5 Global Tachycardia Market, By Type, 2020–2027, (USD Million)

Table 6 Global Tachycardia Market, By Treatment, 2020–2027, (USD Million)

Table 7 Global Tachycardia Market, By Diagnosis, 2020–2027, (USD Million)

Table 8 Global Tachycardia Market, By End-User, 2020–2027, (USD Million)

Table 9 North America Tachycardia Market, By Type, 2020–2027, (USD Million)

Table 10 North America Tachycardia Market, By Treatment, 2020–2027, (USD Million)

Table 11 North America Tachycardia Market, By Diagnosis, 2020–2027, (USD Million)

Table 12 North America Tachycardia Market, By End-User, 2020–2027, (USD Million)

Table 13 U.S. Tachycardia Market, By Type, 2020–2027, (USD Million)

Table 14 U.S. Tachycardia Market, By Treatment, 2020–2027, (USD Million)

Table 15 U.S. Tachycardia Market, By Diagnosis, 2020–2027, (USD Million)

Table 16 U.S. Tachycardia Market, By End-User, 2020–2027, (USD Million)

Table 17 Canada Tachycardia Market, By Type, 2020–2027, (USD Million)

Table 18 Canada Tachycardia Market, By Treatment, 2020–2027, (USD Million)

Table 19 Canada Tachycardia Market, By Diagnosis, 2020–2027, (USD Million)

Table 20 Canada Tachycardia Market, By End-User, 2020–2027, (USD Million)

Table 21 South America Tachycardia Market, By Type, 2020–2027, (USD Million)

Table 22 South America Tachycardia Market, By Treatment, 2020–2027, (USD Million)

Table 23 South America Tachycardia Market, By Diagnosis, 2020–2027, (USD Million)

Table 24 South America Tachycardia Market, By End-User, 2020–2027, (USD Million)

Table 25 Europe Tachycardia Market, By Type, 2020–2027, (USD Million)

Table 26 Europe Tachycardia Market, By Treatment, 2020–2027, (USD Million)

Table 27 Europe Tachycardia Market, By Diagnosis, 2020–2027, (USD Million)

Table 28 Europe Tachycardia Market, By End-User, 2020–2027, (USD Million)

Table 29 Western Europe Tachycardia Market, By Type, 2020–2027, (USD Million)

Table 30 Western Europe Tachycardia Market, By Treatment, 2020–2027, (USD Million)

Table 31 Western Europe Tachycardia Market, By Diagnosis, 2020–2027, (USD Million)

Table 32 Western Europe Tachycardia Market, By End-User, 2020–2027, (USD Million)

Table 33 Eastern Europe Tachycardia Market, By Type, 2020–2027, (USD Million)

Table 34 Eastern Europe Tachycardia Market, By Treatment, 2020–2027, (USD Million)

Table 35 Eastern Europe Tachycardia Market, By Diagnosis, 2020–2027, (USD Million)

Table 36 Eastern Europe Tachycardia Market, By End-User, 2020–2027, (USD Million)

Table 37 Asia Pacific Tachycardia Market, By Type, 2020–2027, (USD Million)

Table 38 Asia Pacific Tachycardia Market, By Treatment, 2020–2027, (USD Million)

Table 39 Asia Pacific Tachycardia Market, By Diagnosis, 2020–2027, (USD Million)

Table 40 Asia Pacific Tachycardia Market, By End-User, 2020–2027, (USD Million)

Table 41 Middle East & Africa Tachycardia Market, By Type, 2020–2027, (USD Million)

Table 42 Middle East & Africa Tachycardia Market, By Treatment, 2020–2027, (USD Million)

Table 43 Middle East & Africa Tachycardia Market, By Diagnosis, 2020–2027, (USD Million)

Table 44 Middle East & Africa Tachycardia Market, By End-User, 2020–2027, (USD Million) 

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation For Global Tachycardia Market

Figure 3 Segmentation Market Dynamics For Tachycardia Market

Figure 4 Global Tachycardia Market Share, By Type 2020

Figure 5 Global Tachycardia Market Share, By Treatment 2020

Figure 6 Global Tachycardia Market Share, By End-User, 2020

Figure 7 Global Tachycardia Market Share, By Region, 2020

Figure 8 North America Tachycardia Market Share, By Country, 2020

Figure 9 Europe Tachycardia Market Share, By Country, 2020

Figure 10 Asia Pacific Tachycardia Market Share, By Country, 2020

Figure 11 Middle East & Africa Tachycardia Market Share, By Country, 2020

Figure 12 Global Tachycardia Market: Company Share Analysis, 2020 (%)

Figure 13 Abbott Laboratories: Key Financials

Figure 14 Abbott Laboratories: Segmental Revenue

Figure 16 Abbott Laboratories: Geographical Revenue

Figure 17 Terumo Corporation.: Key Financials

Figure 18 Terumo Corporation: Segmental Revenue

Figure 19 Terumo Corporation: Geographical Revenue

Figure 20 Medtronic PLC: Key Financials

Figure 21 Medtronic PLC: Segmental Revenue

Figure 22 Medtronic PLC: Geographical Revenue

Figure 23 TZ Medical, Inc.: Key Financials

Figure 24 TZ Medical, Inc.: Segmental Revenue

Figure 25 TZ Medical, Inc.: Geographical Revenue

Figure 26 GlaxoSmithKline Plc: Key Financials

Figure 27 GlaxoSmithKline Plc: Segmental Revenue

Figure 28 GlaxoSmithKline Plc. Geographical Revenue

Figure 29 Essential Medical, Inc.: Key Financials

Figure 30 Essential Medical, Inc.: Segmental Revenue

Figure 31 Essential Medical, Inc.: Geographical Revenue

Tachycardia Market Scenario


Tachycardia is a common type of heart disorder, which results in a faster heartbeat. Tachycardia can be caused due to various conditions such as heart diseases including coronary artery disease, drinking large amounts of alcohol, and medical conditions such as thyroid disease and certain lung diseases.

The tachycardia market is majorly driven by the high prevalence of cardiovascular diseases, high consumption of alcohol, and increasing lung disorders. Additionally, factors such as increasing approvals for vascular closure devices, government initiatives and support, increasing demand for advanced treatment, increasing research and clinical trials for tachycardia, and growing market players offering newer products are likely to drive the market.

Factors that are likely to hamper the growth of the market are the high cost of the treatment and lack of awareness.

The Global Tachycardia Market is expected to grow at a CAGR of 6.5% during the forecast period.

Tachycardia Market Segments  

The global tachycardia market is segmented on the basis of type, treatment, diagnosis, and end-user.


On the basis of type, the market is segmented into atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and tachy-brady syndrome. 


On the basis of treatment, the market is segmented into vagal maneuvers, medications, and cardioversion. On the basis of diagnosis, the market is segmented into imaging tests, electrocardiogram, and stress test.  On the basis of imaging tests, it is further sub-segmented into echocardiogram, MRI, CT scan, coronary angiogram, and chest X-ray.


On the basis of end-user, the market is segmented into ambulatory surgical centers, specialty centers, and hospitals and clinics.


Figure: Global Tachycardia Market, by Region, 2016 (%)


 Tachycardia Market


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis


Tachycardia Market Regional Analysis


The North American tachycardia market is a growing market in the Americas region. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. The increasing number of alcohol consumption and rising prevalence of cardiovascular rates are likely to enhance the growth of vascular closure devices. Additionally, the increasing need for minimally invasive procedures, growing healthcare expenditure, and the rising demand for technologically advanced treatments and products along with the rising government support are likely to enhance the growth of the tachycardia market in North America.


Europe is the second largest market and holds a healthy share in the global tachycardia market. The European market is expected to grow during the forecast period owing to the availability of newer and advanced treatment facilities and healthcare expenditure along with growing need for better healthcare infrastructure. Furthermore, increasing cardiovascular rates, along with rising population inclined towards sedentary lifestyle is driving the growth of the tachycardia market. According to the European Heart Network, in 2015, there were 11.3 million cardiovascular disorder cases in Europe.


Asia Pacific is expected to be the fastest growing market. The increasing prevalence of chronic diseases is the major driver for the market growth. China is the fastest growing region owing to an increasing population. The increasing awareness about health and availability of new treatment methods drives the market in this region. The increasing healthcare expenditure and rise in the standard of living are driving the growth of the tachycardia market in the Asia Pacific region.


The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the development of the healthcare industry and rising availability of specialty care centers.


Tachycardia Market Key Players       


Some of the key players in the Tachycardia market are TZ Medical, Cardiva Medical Inc., Medtronic plc, Terumo Corporation Essential Medical, Inc., Merit Medical Systems, Inc., Abbott, Cardinal Health Inc., Inc., and Vasorum Ltd.


Research Methodology


 Tachycardia Methodology


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis


Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2018-2023: Substantial CAGR
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, Diagnosis, And End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   TZ Medical, Cardiva Medical Inc., Medtronic plc, Terumo Corporation Essential Medical, Inc., Merit Medical Systems, Inc., Abbott, Cardinal Health Inc., Inc., and Vasorum Ltd.
  Key Market Opportunities   Increasing approvals for vascular closure devices and government initiatives
  Key Market Drivers

  • High prevalence of cardiovascular diseases
  • High consumption of alcohol
  • Increasing lung disorders


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Tachycardia is a common type of heart disorder, which results in a faster heartbeat.Β 

    Tachycardia Market is expected to exhibit a strong 6.5% CAGR over the forecast period till 2023.

    growing prevalence of cardiovascular disorders is the major driver for the Tachycardia Market.

    Americas hold a dominant 48% share in the global tachycardia market.

    Leading players in the Tachycardia Market include TZ Medical, Vasorum Ltd., and Medtronic, among others.